Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination therapy approach using separate inhalers: a maintenance inhaler containing fluticasone propionate and salmeterol (such as Advair) plus a rescue inhaler containing albuterol. Fluticasone propionate is an inhaled corticosteroid that works by reducing inflammation and swelling in the lungs. Salmeterol is a long-acting beta-agonist (LABA) that relaxes airway muscles to improve breathing. Albuterol is a short-acting beta-agonist (SABA) used as a rescue medication for acute symptoms. This combination approach addresses both the inflammatory component of respiratory conditions and provides both long-term control and quick relief of symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on albuterol + fluticasone propionate + salmeterol.